DSM Receives European Outsourcing Awards for Carbon Footprint Reducing Technology
PARSIPPANY, N.J., Oct. 7 /PRNewswire/ -- DSM Pharmaceutical Products, the custom manufacturing organization of Royal DSM NV, is pleased to announce that their submission for the European Outsourcing Awards, organized by Via Media UK Ltd, entitled "Achieving substantial carbon dioxide footprint reduction for the scale up of a drug intermediate," was an award recipient at the 6th October ceremony held in Paris, France.
DSM applied their InnoSyn™ route scouting services to launch a collaborative research program to identify a faster route for a drug intermediate using (bio)catalytic processes with the same level of reliability and quality, yet with a reduced carbon footprint of over fifty percent. The new process resulted also in shorter cycle times due to fewer steps in the process.
Andre de Vries, Ph.D., Competence Manager for Homogeneous Catalysis at DSM, commented, "This project involved scientists covering all relevant areas of organic process development, including biocatalysis and homogeneous catalysis. From the 10 new identified routes, all less than 5 steps, the route combining a biocatalytic and a metal-catalyzed step showed to be most sustainable. In this way, DSM as the contract manufacturer is contributing to extending the life cycle of the customer's product using innovation to decrease the eco footprint."
Dr. Kevin Robinson, Editorial Director, Pharma magazine and judging coordinator, stated: "The European Outsourcing Awards judging panel is selected to give an impartial, professional and wide-ranging level of expertise and is assembled exclusively from leading healthcare organisations and top business school academics." DSM was nominated under the categories of Most Improved Process, Plant or Facility, which focuses on expertise and innovation to meet customer requirements for time-to-market, and Best Contract Manufacturing Project, which focuses on production and commercial manufacturing innovation, cost-effectiveness and regulatory compliance.
Organized by Via Media UK Ltd in conjunction with Via Connect, a provider of various forums and events to the bio/pharmaceutical, nutraceutical and personal care industries, the European Outsourcing Awards gala dinner was held in Paris, France, during the week of the CPhI Worldwide trade event.
InnoSyn™ is a trademark of DSM
Via Media UK Ltd and Via Connect
Via Media UK Ltd is a dynamic media company that specialises in producing high quality publications - both printed and digital - for the supply chain, auto-ID, nutraceutical and functional food, pharmaceutical, biopharmaceutical and life science industries, including Pharma Magazine, which is distributed globally across the pharmaceutical, biopharmaceutical and life science industries with a focus on R&D, raw materials, packaging, manufacturing, QA/QC, business, management and marketing.
DSM Pharmaceutical Products
DSM Pharmaceutical Products is a global provider of high quality custom contract manufacturing and development services to the pharmaceutical and biopharmaceutical industries. DSM contract manufacturing services include: chemical development, registered intermediates, registered starting materials, active pharmaceutical ingredients (API's), mammalian cell production of monoclonal antibodies and proteins, formulation development, clinical trial manufacturing and finished dose form manufacturing of solids, semi-solids, and scheduled drugs, aseptic liquid and lyophilized products. More information: www.dsmpharmaceuticalproducts.com
DSM – the Life Sciences and Materials Sciences Company
Royal DSM N.V. creates solutions that nourish, protect and improve performance. Its end markets include human and animal nutrition and health, personal care, pharmaceuticals, automotive, coatings and paint, electrical and electronics, life protection and housing. DSM manages its business with a focus on the triple bottom line of economic performance, environmental quality and social responsibility, which it pursues simultaneously and in parallel. DSM has annual net sales of about €8 billion and employs some 22,700 people worldwide. The company is headquartered in the Netherlands, with locations on five continents. DSM is listed on Euronext Amsterdam. More information: www.dsm.com
For more information:
DSM Forward-looking statements
This press release contains forward-looking statements that involve inherent risks and uncertainties. These statements are based on current expectations, estimates and projections of the management of DSM and information currently available. The statements involve certain risks and uncertainties that are difficult to predict and therefore DSM does not guarantee that their expectations will be realized. Furthermore, DSM has no obligation to update the statements contained in this press release.
SOURCE DSM Pharmaceutical Products
More by this Source
DSM and Tunitas Therapeutics Sign Agreement to Develop Lead Allergy Therapeutic
Dec 03, 2013, 11:00 ET
DSM and Opthea Sign Agreement to Manufacture Opthea's Lead Product for Eye Disease
Oct 29, 2013, 17:55 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.